A controversial Trump administration plan to lower drug costs by pegging prices to what are paid by several foreign countries is getting pushback from dozens of groups. They argue the proposal would import price controls, restrict patient access, and reduce incentives for medical innovation.

In a letter to House and Senate leaders, the groups maintain the proposal is misguided and would ultimately hurt millions of Medicare B beneficiaries. And so, they urged the lawmakers to end the proposed pilot program and instead consider implementing some of the ideas in a limited fashion.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy